-
公开(公告)号：US11965029B2
公开(公告)日：2024-04-23
申请号：US17339301
申请日：2021-06-04
Applicant: Amgen Inc.
Inventor： Dirk E. Smith , Ian Foltz , Chadwick T. King , Ai Ching Lim , Rutilio Clark , Michael R. Comeau , Randal R. Ketchem , Donghui Shi , Xiaoshan Min , Zhulun Wang
CPC classification number: C07K16/2866 , C07K16/244 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N15/11
Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
-
公开(公告)号：US11186636B2
公开(公告)日：2021-11-30
申请号：US16500378
申请日：2018-04-20
Applicant: AMGEN INC.
Inventor： Ian Foltz , Shilpa Sambashivan , Irwin Chen , Susie Miki Harris , Dora Toledo Warshaviak , Ian Driver , Daniel Lu
Abstract: The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described.
-
公开(公告)号：US20190270817A1
公开(公告)日：2019-09-05
申请号：US16245733
申请日：2019-01-11
Applicant: AMGEN INC.
Inventor： Khaled M.K.Z. Ali , Neeraj Jagdish Agrawal , Gunasekaran Kannan , Ian Foltz , Zhulun Wang , Daren Bates , Marissa Mock , Shunsuke Takenaka
Abstract: Provided herein are PD-1 antigen-binding proteins and related nucleic acids, vectors, host cells, kits and pharmaceutical compositions. Methods of making PD-1 antigen-binding proteins and methods of treating a subject are further provided.
-
4.发明授权Methods of using an alpha-4-beta-7 heterodimer specific antagonist antibody 有权使用α-4-β-7异二聚体特异性拮抗剂抗体的方法公开(公告)号：US09499620B2
公开(公告)日：2016-11-22
申请号：US14497883
申请日：2014-09-26
Applicant: AMGEN INC.
Inventor： Hailing Hsu , Ian Foltz , Frederick Jacobsen , Taruna Arora
IPC: A61K39/395 , C07K16/18 , C07K16/28
CPC classification number: C07K16/2839 , C07K16/28 , C07K2317/21 , C07K2317/24 , C07K2317/32 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.
Abstract translation: 公开了alpha4beta7异源二聚体特异性抗原结合蛋白，编码它们的核酸，以及制备和使用它们的方法。
-
5.发明申请公开(公告)号：US20150086563A1
公开(公告)日：2015-03-26
申请号：US14497883
申请日：2014-09-26
Applicant: AMGEN INC.
Inventor： Hailing Hsu , Ian Foltz , Frederick Jacobsen , Taruna Arora
IPC: C07K16/28
CPC classification number: C07K16/2839 , C07K16/28 , C07K2317/21 , C07K2317/24 , C07K2317/32 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.
Abstract translation: 公开了alpha4beta7异源二聚体特异性抗原结合蛋白，编码它们的核酸，以及制备和使用它们的方法。
-
Patent Agency Ranking
公开(公告)号：US09982054B2
公开(公告)日：2018-05-29
申请号：US15178652
申请日：2016-06-10
Applicant: Amgen Inc.
Inventor： Dirk E. Smith , Ian Foltz , Chadwick T. King , Ai Ching Lim , Rutilio Clark , Michael R. Comeau , Randal R. Ketchem , Donghui Shi , Xiaoshan Min , Zhulun Wang
CPC classification number: C07K16/2866 , A61K2039/505 , C07K16/244 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N15/11
Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
-
公开(公告)号：US20170275365A1
公开(公告)日：2017-09-28
申请号：US15347233
申请日：2016-11-09
Applicant: AMGEN INC.
Inventor： Hailing Hsu , Ian Foltz , Frederick Jacobsen , Taruna Arora-khare
IPC: C07K16/28
CPC classification number: C07K16/2839 , C07K16/28 , C07K2317/21 , C07K2317/24 , C07K2317/32 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.
-
公开(公告)号：US11541103B2
公开(公告)日：2023-01-03
申请号：US16054035
申请日：2018-08-03
Applicant: AMGEN INC.
Inventor： Khaled M. K. Z. Ali , Neeraj Jagdish Agrawal , Gunasekaran Kannan , Ian Foltz , Zhulun Wang , Darren Bates , Marissa Mock , Shunsuke Takenaka
Abstract: Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.
-
公开(公告)号：US10227414B2
公开(公告)日：2019-03-12
申请号：US15601868
申请日：2017-05-22
Applicant: Amgen Inc.
Inventor： Dirk E. Smith , Ian Foltz , Chadwick T. King , Ai Ching Lim , Rutilio Clark , Michael R. Comeau , Randal R. Ketchem , Donghui Shi , Xiaoshan Min , Zhulun Wang
Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
-
公开(公告)号：US09464139B2
公开(公告)日：2016-10-11
申请号：US14472116
申请日：2014-08-28
Applicant: AMGEN INC.
Inventor： Courtney Beers , Jason C. O'Neill , Ian Foltz , Randal R. Ketchem , Julia C. Piasecki
CPC classification number: C07K16/2878 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/565 , C07K2317/71 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/77 , C07K2317/94
Abstract: Antigen binding proteins that activate GITR are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided. The antigen binding proteins have value in therapeutic methods in which it is useful to stimulate GITR signaling, thereby inducing or enhancing an immune response in a subject. Accordingly, the antigen binding proteins have utility in a variety of immunotherapy treatments, including treatment of various cancers and infections.
Abstract translation: 提供激活GITR的抗原结合蛋白。 还提供了编码抗原结合蛋白的核酸和含有此类核酸的载体和细胞。 抗原结合蛋白在治疗方法中具有价值，其中它可用于刺激GITR信号传导，从而诱导或增强受试者的免疫应答。 因此，抗原结合蛋白具有多种免疫治疗方法的用途，包括治疗各种癌症和感染。
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.025 seconds)
